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Metastasis	is	a	major	cause	of	mortality	in	cancer	patients.	However,	the	mechanisms	governing	the	metastatic	
process	remain	elusive,	and	few	accurate	biomarkers	exist	for	predicting	whether	metastasis	will	occur,	some-
thing	that	would	be	invaluable	for	guiding	therapy.	We	report	here	that	the	carboxypeptidase	E	gene	(CPE)	is	
alternatively	spliced	in	human	tumors	to	yield	an	N-terminal	truncated	protein	(CPE-ΔN)	that	drives	metasta-
sis.	mRNA	encoding	CPE-ΔN	was	found	to	be	elevated	in	human	metastatic	colon,	breast,	and	hepatocellular	
carcinoma	(HCC)	cell	lines.	In	HCC	cells,	cytosolic	CPE-ΔN	was	translocated	to	the	nucleus	and	interacted	
with	histone	deacetylase	1/2	to	upregulate	expression	of	the	gene	encoding	neural	precursor	cell	expressed,	
developmentally	downregulated	gene	9	(Nedd9)	—	which	has	been	shown	to	promote	melanoma	metastasis.	
Nedd9	upregulation	resulted	in	enhanced	in	vitro	proliferation	and	invasion.	Quantification	of	mRNA	encod-
ing	CPE-ΔN	in	HCC	patient	samples	predicted	intrahepatic	metastasis	with	high	sensitivity	and	specificity,	
independent	of	cancer	stage.	Similarly,	high	CPE-ΔN	mRNA	copy	numbers	in	resected	pheochromocytomas/
paragangliomas	(PHEOs/PGLs),	rare	neuroendocrine	tumors,	accurately	predicted	future	metastasis	or	recur-
rence.	Thus,	CPE-ΔN	induces	tumor	metastasis	and	should	be	investigated	as	a	potentially	powerful	biomarker	
for	predicting	future	metastasis	and	recurrence	in	HCC	and	PHEO/PGL	patients.
Introduction
Cancer mortality often results from metastatic disease and is not the 
direct effect of the primary tumor. With advances in cancer treat-
ment, control of the primary tumor can be managed by multimodal 
therapy; however, metastatic disease is frequently refractory to the 
same therapeutic approaches. Thus, identification of biomarkers 
that could accurately predict future metastasis from the state of the 
primary tumor would be invaluable for guiding therapy.
Currently, determination of the likelihood of developing meta-
static disease is based on morphological and histological criteria 
such as the size of the primary tumor, local invasion, tumor dif-
ferentiation together with vascular and capsular invasion, and 
the presence of cancer cells in lymph nodes. Although these cri-
teria put many patients in a very high-risk category for metastatic 
disease, a significant number of them do not develop metastatic 
spread. On the other hand, patients with favorable conventional 
prognostic factors may still develop metastasis.
Numerous mechanisms have been described that modulate 
metastatic potential, including those both endogenous and 
exogenous to the tumor cells. Such alterations may recruit genes 
or proteins crucial in the pathogenesis of metastatic spread, 
recurrence, or significant local invasiveness. Recently, several 
studies have identified markers of metastatic spread or to pre-
dict metastasis. The density of a tumor microenvironment of 
metastasis, defined as the tripartite arrangement of an invasive 
breast carcinoma cell, a macrophage, and an endothelial cell, 
was found to predict the development of systemic, hematog-
enous metastases in human breast carcinoma (1). Genetic pro-
filing, pointing toward chromosomal aberrations in patients 
with early-stage colorectal cancer, identified patients who devel-
oped metastatic relapse (2). Murine double minute oncogene 
(Mdmp2) and Ki-67 are well established as important predictors 
of metastasis in some cancers (3). However, identifying a prog-
nostic marker that would be common to various cancers in their 
ability to predict development of metastasis or recurrence is of 
utmost importance. Elucidating and studying new molecules 
that drive tumor metastasis could lead to a better understand-
ing of the mechanisms underlying this complex process (4, 5) 
and also provide potential prognostic markers and therapeutic 
targets for clinical use. In the present study we show, for the 
first time to our knowledge, that a splice isoform of the pro-
hormone processing enzyme carboxypeptidase E (CPE) (6, 7), 
CPE-ΔN, induces tumor growth and metastasis and is a power-
ful biomarker for predicting future development of extra- and 
intrahepatic metastasis (recurrence) in patients with hepatocel-
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lular carcinoma (HCC; as an epithelial cell–derived tumor) and 
pheochromocytoma/paraganglioma (PHEO/PGL; as a neuroen-
docrine cell–derived tumor).
CPE is a Co++ activated metalloexopeptidase with a pH optimum 
of 5.5 and is found primarily in endocrine and neuroendocrine 
cells (6). Peptide hormones and neuropeptides are synthesized as 
precursors at the rough endoplasmic reticulum, transported to 
the Golgi complex, and packaged into secretory granules, where 
they are processed sequentially, first by prohormone convertas-
es (PC1/3 and PC2), which cleave on the carboxyl side of paired 
basic residues to yield basic residue-extended peptides (8). Soluble 
CPE (MW ~53 kDa) then cleaves the basic residues to generate 
biologically active peptide hormones and neuropeptides (6, 7). 
An approximately 55-kDa membrane form of CPE anchored to 
cholesterol/sphingolipid-rich microdomains at the trans-Golgi 
network (TGN) functions as a receptor for sorting prohormones 
into the regulated secretory pathway granules for secretion (9, 10). 
Hence, mice with Cpe mutations that lack CPE, and Cpe-knockout 
mice, have many pathophysiological conditions, such as diabetes, 
infertility, obesity, low bone mineral density, and deficits in learn-
ing and memory (11–14).
CPE of various molecular weights, some different from the 55-kDa 
WT CPE, have been found in human pulmonary neuroendocrine 
tumors (15), insulinomas (16), and epithelial-derived hepatomas 
(17). Moreover, high-throughput microarray studies have corre-
lated elevated CPE mRNA levels with tumorigenesis in a number 
of non-endocrine cancers, including colon-rectal, renal, and cervical 
cancers (GEO Profile ID: GDS2609, GDS1780, GDS505, GDS2416; 
see Bioinformatics section in Methods). However, the role of CPE in 
tumor progression was undescribed. Alternative splicing of mRNA 
transcripts can result in proteins that either function differently 
or are localized to different cellular compartments compared with 
their primary transcript (18–20). Given a possible new role of this 
obesity susceptibility gene, Cpe (21), in tumorigenesis, independent 
of its enzymatic function, we carried out a bioinformatics search (see 
Methods) for alternatively spliced transcripts of this gene. A splice 
variant transcript of the Cpe gene, which encodes an isoform of 
CPE lacking the N-terminus (CPE-ΔN), was identified (Figure 1A). 
Its expression was associated with an increase in the expression of 
the neural precursor cell expressed, developmentally downregu-
lated gene 9 (Nedd9) and with cell proliferation in mouse Neuro2a 
cells, a neuroendocrine cell line (our unpublished data). NEDD9 is 
expressed transiently during embryonic development, and its expres-
sion is downregulated in adult mice (22, 23). It has been implicated 
in cancer development (24, 25) and tumor cell migration (26), and 
has been identified as a metastasis-promoting gene in melano-
mas (27), where it has distinct roles in proliferation and invasion 
of melanoma cells. NEDD9 enhances the invasion and metastasis 
of melanocytes by interacting with focal adhesion kinase (FAK), 
which increases focal contact formation and cell attachment, to the 
extracellular matrix. The mechanism of action of NEDD9 in migra-
tion and invasion via interaction with the FAK-CAS-Crk-DOCK180 
complex is well described (27, 28). Hence, we investigated the expres-
sion of CPE-ΔN and its action in inducing Nedd9 gene expression, 
growth, and metastasis in human cancers. In translational studies, 
we determined that CPE-ΔN could serve as a prognostic biomarker 
for predicting future metastasis and recurrence in patients with can-
cers of different origin, HCC and PHEO/PGL.
Results
CPE-ΔN is highly expressed in human metastatic tumor cell lines, and 
repression in xenograft tumors decreased metastatic lesions in mice. To 
investigate the role of CPE-ΔN in tumor metastasis, we used 
human HCC cells as a model system. Semiquantitative RT-PCR 
using specific primers showed that highly metastatic MHCC97H 
cells had elevated levels of CPE-ΔN mRNA compared with cells 
with low metastatic potential (MHCC97L) derived from the same 
parental cell line (Figure 1B). Northern blotting confirmed a CPE 
transcript of approximately 2.4 kb, consistent with the predicted 
size of CPE-ΔN mRNA, different from the WT CPE transcript, 
which is 2.5 kb in size (ref. 29 and Figure 1C).
Moreover, WT CPE mRNA (see Methods) and protein (our 
unpublished observations) were not detected in these epithelial-
derived MHCC97 cells. qRT-PCR showed that the CPE-ΔN mRNA 
level was 8.5-fold higher in MHCC97H versus MHCC97L cells 
(Figure 2A). However, a normal hepatocyte cell line, LO2, showed 
essentially no expression of CPE-ΔN mRNA compared with HCC 
cell lines (Supplemental Figure 1; supplemental material available 
Figure 1
Schematic and characterization of ΔN-splice variant of CPE in HCC 
cells. (A) Diagram showing human WT and human ΔN-splice variant 
CPE-ΔN mRNA and protein derived from bioinformatic analysis (see 
Methods). (B) Semiquantitative PCR showing the 148-bp predicted 
product of CPE-ΔN and 18S RNA in high (H) and low (L) metastatic 
MHCC97 cells after 31 cycles of co-amplification. (C) Northern blot 
showing the CPE-ΔN transcript of approximately 2.4 kb in MHCC97H 
cells. (D) Western blot showing the endogenous ΔN-splice variant 
CPE-ΔN product in MHCC97H cells. The identity of the approximately 
40-kDa band as hCPE-ΔN isoform was verified by immunostaining 
with both a mouse monoclonal CPE antibody and a rabbit polyclonal 
antibody (no. 6135) generated against a CPE peptide (mouse pre-pro-
CPE amino acids 362–379) in our laboratory. Furthermore, absorption 
control with the antigenic peptide abolished this approximately 40-kDa 
band. The left lane was run on a separate blot; the right two lanes were 
run on the same blot but were noncontiguous.
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online with this article; doi:10.1172/JCI40433DS1). The transla-
tion product of the human CPE-ΔN splice variant transcript in 
HCC cells has an apparent molecular mass of approximately 40 
kDa (Figure 1D). Two other highly metastatic human tumor 
cell lines from HCC also had elevated expression of CPE-ΔN 
mRNA (Figure 2A), the approximately 40-kDa CPE-ΔN protein, 
and NEDD9 protein compared with matched tumor lines with 
low metastatic potential (Figure 2B). The form of NEDD9 that 
increased with metastatic potential in these cells was primarily 
a 70-kDa form that likely represents a cleavage product of the 
105/115-kDa full-length NEDD9 (30). An approximately 35-kDa 
N-terminal band was also detected with an antibody directed 
against the N-terminal region (Supplemental Figure 2).
To demonstrate that CPE-ΔN induces growth and cell invasion, 
highly metastatic human liver MHCCLM3 cells were downregu-
lated in CPE-ΔN expression by siRNA. Suppression of CPE-ΔN 
expression in highly metastatic MHCCLM3 cells led to inhibition 
of growth and invasion (Supplemental Figure 3). Furthermore, in 
each of the 3 clones stably transduced with 3 different CPE siRNA 
sequences, a decrease in NEDD9 was also observed (Figure 2C). To 
complement these observations in vivo, we used two animal mod-
els. In one, nude mice were subcutaneously injected in the right 
flank with luciferase-expressing MHCCLM3 cells transduced with 
either si-CPE-ΔN (sequence 2) or si-Scr (Figure 3A and ref. 31). 
Thirty days after cell inoculation, bioluminescence imaging 
showed that control mice bearing the si-Scr MHCCLM3 cells had 
tumors 16.2-fold greater in intensity than mice injected with si-
CPE-ΔN cells. In another model, a metastatic orthotopic mouse 
model (Figure 3B and ref. 32), the tumors from mice described in 
the first model above were removed, cut into 1- to 2-mm cubes, 
and implanted into the liver of nude mice (32). Thirty-five days 
after implantation, bioluminescence imaging showed that the si-
Scr MHCCLM3–derived tumors in the mice were 13.9-fold greater 
in intensity compared with those from si-CPE-ΔN–treated cells. 
They also developed intrahepatic metastasis and extrahepatic 
metastasis to the lung (Figure 3B and Supplemental Figure 4) as 
previously described (33). Mice inoculated with si-CPE-ΔN MHC-
CLM3–derived tumors had smaller tumors and showed no metas-
tasis. These in vitro and in vivo results demonstrate that CPE-ΔN 
promotes HCC growth and metastasis.
Similar results were observed in other human tumor cell lines. 
Highly metastatic breast, colon, and head and neck cancer cells 
had elevated expression of CPE-ΔN mRNA compared with 
matched tumor cell lines with low metastatic potential (Figure 4). 
Western blot analysis of these cell lines (MDA-MB-231, HT-29, and 
MDA-1986) showed expression of only CPE-ΔN but not WT CPE 
(data not shown). Suppression of CPE-ΔN by the stably transfected 
siRNA in these cell lines (Supplemental Figure 3A) led to 56%–85% 
inhibition of growth (Supplemental Figure 3B) and 70%–85% inhi-
bition of Matrigel invasion (Supplemental Figure 3C).
CPE-ΔN drives tumor invasion by interacting with HDAC1/2 to upregu-
late Nedd9 metastasis gene expression. To determine whether CPE-ΔN 
promotes tumor growth and invasion through activation of 
Nedd9 gene expression, we transfected low metastatic MHCC97L 
cells with CPE-ΔN cDNA. Concomitant with an increase in Nedd9 
mRNA upon transfection (2.99 ± 0.76–fold; P < 0.001, n = 3), the 
transfected cells exhibited elevated levels of both CPE-ΔN and 
NEDD9 protein (Figure 5A). Consequently, significant increases 
in proliferation and invasion compared with cells transfected 
with an empty vector were seen (Figure 5B). This enhanced inva-
sion was suppressed when these MHCC97L cells stably express-
ing CPE-ΔN were infected with lentivirus carrying Nedd9 siRNA 
Figure 2
Elevated expression of CPE-ΔN and NEDD9 in metastatic tumor cell lines. (A) qRT-PCR quantification of hCPE-ΔN mRNA in HCC tumor cell 
lines. Graphs show fold difference in expression of CPE-ΔN mRNA in tumor cell lines relative to primary tumor cells with lowest hCPE-ΔN mRNA 
expression (first blue bar) made equal to 1. Red bars, highly metastatic cell lines; blue bars, low metastatic cell lines. Note higher expression 
of hCPE-ΔN mRNA in the highly metastatic cell lines compared with low metastatic cells. Asterisks indicate known highly metastatic or aggres-
sive cell lines. Assays were done in quadruplicate. (B) Top: Western blots showing approximately 40 kDa hCPE-ΔN and 70 kDa NEDD9 in 
HCC tumor cell lines. Bottom: The intensities of the bands from the Western blots were quantified by densitometry. Graphs show expression 
levels of hCPE-ΔN (blue) and NEDD9 (red) for each cell line, corrected for actin levels and expressed as mean ± SEM in arbitrary units (n = 3 
experiments). (C) Western blot showing approximately 40 kDa CPE-ΔN and 70 kDa NEDD9 in highly metastatic HCC cells (MHCCLM3). Cells 
were infected with si-Scr or CPE-ΔN siRNA (sequences 1, 2, 3) to downregulate CPE-ΔN mRNA expression. All 3 clones showed coordinated 
downregulation of CPE-ΔN and NEDD9 protein.
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to downregulate NEDD9 expression (Figure 5, C and D). This 
result provides direct evidence that CPE-ΔN promoted cell inva-
sion by driving up Nedd9 gene expression.
Thus, CPE-ΔN, which lacks the signal peptide, can be translocated 
into the nucleus to modulate gene expression. This is consistent with 
a recent high-throughput protein-protein interaction study that 
showed a direct interaction of CPE with a chromodomain-helicase-
DNA-binding protein (CHD3)/histone deacetylase (HDAC1 and -2) 
complex (34); however, the authors did not relate a physiological 
significance to this interaction. Our bioinformatic studies (see 
Methods) identified a domain homologous to HDAC-interacting 
proteins in CPE-ΔN (human CPE amino acids 111–196, with a con-
sensus of 60%) (35). Hence, we carried out co-immunoprecipitation 
studies. Our results indicate that CPE-ΔN interacts with HDAC1/2 
Figure 3
CPE-ΔN induces growth and metastasis in animal models. (A) MHCCLM3 cells transduced with luciferase and expressing si-Scr or CPE-ΔN siRNA 
were injected subcutaneously into the flanks of BALB/c nu/nu mice. Images shown are pseudoimages of emitted light in photons/second/cm2/ 
steradian, superimposed over the gray scale photographs of the animal at day 0 and day 30. Mean intensity ± SEM of the tumor for si-Scr 
was 4.92 × 108 ± 0.152 × 108 (n = 5) and for si-CPE-ΔN was 3.04 × 107 ± 0.182 × 107 (n = 5). (B) MHCCLM3 cells transduced with luciferase-
labeled si-Scr or si-CPE-ΔN were injected into the flanks of mice. Once the tumor reached approximately 1.5 cm in diameter, it was removed, 
cut into 1- to 2-mm cubes, and implanted into the livers of nude mice. Mice were imaged on days 0 and 35 after tumor inoculation. At day 35, 
the mouse inoculated with si-Scr cells showed metastasis to lung and intestines, but no metastasis occurred in the mouse inoculated with si-
CPE-ΔN cells. n = 5 pairs of animals.
Figure 4
CPE-ΔN mRNA levels correlate with highly metastatic cell lines from various human cancers. qRT-PCR quantification of hCPE-ΔN mRNA in 
breast, colon, and head and neck (H&N) tumor cell lines. Graphs show fold difference in expression of CPE-ΔN mRNA in tumor cell lines rela-
tive to primary tumor cells with lowest hCPE-ΔN mRNA expression (first blue bar in each graph) made equal to 1. Red bars, highly metastatic 
cell lines; blue bars, low metastatic cell lines. Note higher expression of hCPE-ΔN mRNA in the highly metastatic cell lines compared with low 
metastatic cells. Asterisks indicate known highly metastatic or aggressive cell lines. Assays were done in quadruplicate.
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(Figure 6B). HDAC1 and -2 are known to modulate gene transcription 
through histone deacetylation and mediate human tumorigenesis 
(36, 37). To determine whether upregulation of NEDD9 expression is 
dependent on HDAC activity, we treated HCC97L cells stably express-
ing CPE-ΔN with the HDAC inhibitors depsipeptide (Figure 6C) 
and trichostatin A (TSA) (Supplemental Figure 5) at different con-
centrations. Inhibition of HDAC activity by both inhibitors sup-
pressed expression of NEDD9 in these HCC cells, while there was 
no effect on CPE-ΔN expression. Thus, CPE-ΔN upregulates Nedd9 
gene expression, through its interaction with HDAC1/2, to induce 
tumor cell proliferation and migration.
CPE-ΔN is a powerful prognostic biomarker for predicting future metas-
tasis in HCC patients. We evaluated CPE-ΔN as a potential prognostic 
biomarker for predicting future extrahepatic or intrahepatic metas-
tasis (also referred to as recurrence) in HCC patients using two ret-
rospective cohorts of patients. In one group of 99 patients, qRT-PCR 
was used to measure CPE-ΔN mRNA in the primary tumor (T) 
and surrounding non-tumor tissue (N); in a separate group of 
80 patients, Western blotting was used to measure protein levels 
in the tumor and non-tumor tissues. RT-PCR and Western blot-
ting confirmed that only CPE-ΔN mRNA and no WT CPE mRNA 
or protein was expressed in primary HCC tumors (see Methods). 
CPE-ΔN mRNA tumor versus non-tumor was expressed as a ratio 
(T/N). The cutoff value for T/N of greater than 2 for prediction of 
future recurrence was first established using a subset of 37 of the 
99 patients (the training set; see Reporting Recommendations for 
Tumor Marker Prognostic Studies [REMARK] guidelines, ref. 38; 
compliance in Supplemental Data). Then 62 additional HCC 
patients were studied as a test or confirmatory set to independent-
ly assess the usefulness of this cutoff value. Of patients evaluable 
2 years after surgery for disease-free status (no metastasis/recur-
rence), 75.8% (25 of 33) of those who were disease-free had CPE-ΔN 
mRNA ratios of 2 or less, whereas 92.3% (24 of 26) of the patients 
with recurrence had a T/N ratio greater than 2 (Tables 1, 2, and 3).
Complementing this result, when the 99 patients were divided 
into those who showed recurrence at any time during follow-up 
versus those that did not, a dramatic difference in mean T/N val-
ues between the two groups was observed (Figure 7A). Thus, high 
levels of CPE-ΔN mRNA correlate with metastasis/recurrence. A 
Kaplan-Meier plot of disease-free survival of the 62 confirmatory 
HCC patients (Figure 7B) showed shorter disease-free survival 
times (P < 0.0001) when CPE-ΔN mRNA T/N ratios were greater 
than 2 (high) in the primary tumor compared with patients with 
T/N values of 2 or less (low).
Western blots of resected tumors from an additional cohort 
of 80 HCC patients also showed significantly higher CPE-ΔN 
(Figure 8A) levels in patients with recurrence compared with the 
disease-free group. Quantitative analysis (Figure 8B) of the T/N 
ratios of CPE-ΔN protein from such Western blots from these 
80 patients revealed that 82.4% (28 of 34) of the patients with 
primary HCC who were disease-free 6 months after surgery had 
tumor CPE-ΔN T/N levels of 2 or less, whereas 76% (35 of 46) of 
the patients who developed intra- or extrahepatic metastasis with-
in 6 months had primary tumor CPE-ΔN T/N levels of greater 
than 2. Analysis of NEDD9 expression in resected HCC tumors of 
these patients showed significantly elevated levels in the recurrent 
group versus the non-recurrent group (Supplemental Figure 6). 
Immunohistochemistry (IHC) of CPE-ΔN in HCC tumors from 
37 patients revealed immunostaining primarily in the nuclei of 
tumor cells in patients who subsequently developed recurrence 
that was absent in cell nuclei of patients who remained disease-
free (Figure 8, C–F). The intensity of immunostaining determined 
by image analysis (0.402 ± 0.032 vs. 0.279 ± 0.036, mean ± SEM) 
was statistically different (P < 0.02) between the groups. CPE-ΔN 
was further evaluated as a biomarker for HCC, following REMARK 
guidelines (see Supplemental Data).
As noted above, statistical analyses revealed that CPE-ΔN mRNA 
T/N ratios with a cutoff of greater than 2 predicted future recur-
rence within 2 years after surgery, with a sensitivity value of 92.3% 
and a specificity value of 75.8% (Table 2); similar values, 90% and 
78%, respectively, were obtained for patients with recurrence 3 
years after surgery (data not shown). Very importantly, correla-
tion of a high CPE-ΔN mRNA T/N ratio (>2), with recurrence 
did not appear to be dependent on the clinicopathological stage 
of the cancer (Table 3) — despite the inherent imprecision aris-
ing from small sample sizes within stages, the odds ratios (ORs) 
for the impact of a CPE-ΔN ratio greater than 2 in all 3 higher 
stages were consistent, ranging from 13.3 to 62.1. There were HCC 
Figure 5
CPE-ΔN increases cell invasion by upregulating NEDD9 expression. (A) Western blot showing approximately 40 kDa CPE-ΔN and 70 kDa NEDD9 in 
low metastatic HCC cells (MHCC97L), stably transfected with empty vector (EV) or CPE-ΔN cDNA. NEDD9 expression was upregulated upon CPE-ΔN 
overexpression. (B) Colony (left) and Matrigel invasion (right) assays showed increased proliferation (1.9 ± 0.1–fold, SEM, n = 3, ***P < 0.0001) and 
invasion (2.7 ± 0.2 fold, SEM, n = 5, **P = 0.0026), respectively, in cells transfected with CPE-ΔN cDNA versus EV. (C) Western blot showing approxi-
mately 40 kDa CPE-ΔN and 70 kDa NEDD9 in MHCC97L cells stably transfected with EV or CPE-ΔN cDNA and transduced with lentivirus carrying 
NEDD9 siRNA (Si) or scrambled (Scr) siRNA. (D) The increased invasion of MHCC97L cells overexpressing CPE-ΔN was prevented by treatment of 
cells with NEDD9 siRNA (Scr: 4.6 ± 0.1–fold, mean ± SEM, n = 3, versus Si: 1.5 ± 0.3–fold, mean ± SEM, n = 3, **P = 0.002).
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patients with early, stage 2 tumors who had a CPE-ΔN mRNA T/N 
greater than 2 and experienced recurrence, while some patients 
with late, stage 3 and 4 tumors who had CPE-ΔN mRNA T/N less 
than 2 showed no recurrence 2 or 3 years after surgery. In a logistic 
regression model for predicting recurrence within 2 years, CPE-ΔN 
added very significantly to cancer stage as a predictor (OR, 37.6; 
95% CI, 6.7–210.6 with associated P = 1.8 × 10–7).
High CPE-ΔN mRNA copy numbers in resected tumors predicted metastasis 
and recurrence in PHEO/PGL patients. To evaluate CPE-ΔN as a 
prognostic biomarker for another type of cancer, we carried out a 
prospective study on patients with pheochromocytomas/paragan-
gliomas (PHEOs/PGLs), rare tumors of neuroendocrine origin. 
These tumors are often fatal due to catecholamine excess or devel-
opment of metastatic disease (39). Currently, there are no reliable 
markers that would predict malignant behavior of these tumors. 
Among familial syndromes in PHEO/PGL, those related to succi-
nate dehydrogenase subunit B gene mutations (SDHB) are known 
to have a high frequency of metastatic disease (40). Here we ana-
lyzed tumors from 8 patients with SDHx gene mutations (6 with 
SDHB and 2 with subunit D [SDHD] mutations); 5 patients with 
RET gene mutation, which leads to multiple endocrine neoplasia 
type 2 (MEN2); and 1 patient who had SDHB gene polymorphism 
(patient S18) of unclear clinical significance, but with metastatic 
disease at an initial diagnosis. CPE-ΔN mRNA copy numbers in 
the resected tumors were determined, since surrounding normal 
tissue for comparison was unobtainable. Patients in the SDHB/D 
category diagnosed with metastatic tumors at time of surgery had 
tumor CPE-ΔN mRNA copy numbers of 5–11 million, compared 
with 150–200 thousand in 4 patients with primary solitary or mul-
tiple benign tumors (based on their location and behavior); these 4 
patients were disease free with regular follow-up from 2 to 4 years 
after resection (Table 4). However, a fifth patient (S31), with a 
benign tumor at resection, had a CPE-ΔN mRNA copy number 
similar to that in metastatic tumors (Table 4) and hence was pre-
dicted to develop recurrent or metastatic disease. At 2 years of 
follow-up, this patient was documented to have a local recurrence 
Figure 6
CPE-ΔN interacts with HDAC1/2 to upregulate NEDD9 expression. (A) Immunofluorescence confocal microscopy of MHCCLM3 cells transfected 
with si-Scr (top row) or CPE-ΔN siRNA (bottom row). Cells were immunostained with CPE monoclonal antibody and TRITC-conjugated goat anti-
mouse IgG secondary antibody (red). The slide was counterstained with fluorescein phalloidin for F-actin (green) and DAPI for nuclei (blue). Note 
CPE-ΔN in the nucleus of MHCCLM3 si-Scr cells. Original magnification, ×600. (B) MHCC97L cells were transduced with an adenovirus express-
ing CPE-ΔN. Twenty-four hours after transduction, a cell lysate was prepared and immunoprecipitated with CPE or HDAC1 monoclonal antibodies 
as indicated. The immunoprecipitated proteins were analyzed by Western blot for both CPE and HDAC1 and HDAC2. Nonspecific monoclonal 
antibodies (IgG) or omission of antibodies (None) were used as negative controls as indicated. HDAC1 and HDAC2 (two forms) were detected in 
the lanes (CPE) where CPE-ΔN was immunoprecipitated. CPE-ΔN was detected in the lane where HDAC1 was immunoprecipitated, indicating 
interaction of CPE-ΔN with HDAC1- and HDAC2-containing complex. Asterisks indicate IgG heavy and light chains. (C) Effect of HDAC inhibi-
tor depsipeptide on NEDD9 levels in MHCC97L cells stably expressing CPE-ΔN. Cells were treated with depsipeptide at various concentrations 
(0–2 ng/ml) for 24 hours. Cells were harvested and fractionated into cytosolic and nuclear fractions and analyzed by Western blot. A representative 
Western blot shows expression of NEDD9 in cytoplasm (c) and CPE-ΔN in nucleus (n) at different concentrations of depsipeptide, as indicated. 
The graph shows the quantification of NEDD9 and CPE-ΔN bands from Western blots of 3 different experiments. Values are the mean ± SEM.
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with metastasis to bone. In the MEN2 category, 4 patients had 
resected benign primary PHEO and 1 patient (M06) had recurrent 
adrenal PHEO (Table 4). Of these 5 patients, 2 (M05 and M06) 
had high tumor CPE-ΔN mRNA copy numbers (6.8–14.8 million) 
compared with the other 3 who had tumor CPE-ΔN mRNA copy 
numbers in the 170–200 thousand range, similar to those found 
in SDHD/B patients with non-metastatic tumors. In follow-up 
studies, 2 of these low-copy-number patients were disease free for 
6.5 and 6 years, respectively; the third was not available for sub-
sequent follow-up. However, both patients, M05 and M06, who 
were predicted to develop metastasis/recurrence based on their 
high CPE-ΔN mRNA copy numbers, were found to have recur-
rence of PHEO in the surgical bed at 8 and 4 years, respectively. 
CPE-ΔN was further evaluated as a biomarker for PHEO/PGL, fol-
lowing REMARK guidelines (see Supplemental Data). With poor 
outcome in these patients defined as either having metastatic 
disease (SDHx) at the time of resection or development of a post-
resection recurrence (MEN2), high CPE-ΔN mRNA copy numbers 
(e.g., >1 million) correlated with poor outcome, while low copy 
numbers correlated with disease-free survival, with sensitivity and 
specificity values of 100% (Table 5; cut-points for copy numbers 
over a wide range gave identical results). These results indicate 
that CPE-ΔN is a powerful prognostic biomarker for metastatic 
SDHB or recurrent MEN2 PHEO/PGL.
Discussion
Initially, in pilot studies we found, in cDNA microarray analy-
sis comparing gene expression profiles of highly metastatic 
MHCC97H and low metastatic MHCC97L cells derived from 
the same parental cell line, that one of the genes expressed at 
highest levels in MHCC97H cells was CPE. Western blotting and 
immunostaining of MHCC97H cells (Figure 6A) revealed an 
approximately 40-kDa CPE protein localized in the nucleus. The 
decreased size and nuclear localization of immunoreactive CPE 
in these cells, which differ from those of WT CPE, prompted us 
to link the smaller splice variant form of CPE lacking the N-ter-
minal signal peptide we obtained from a bioinformatic search to 
cancer metastasis. In this study, we have characterized the alter-
natively spliced CPE gene transcript encoding CPE-ΔN, a CPE 
isoform, and show that it plays a pivotal role in driving tumor 
metastasis, invasion, and recurrence through what we believe to 
be a novel mechanistic pathway. This CPE isoform, lacking an 
amino-terminal domain, has a distinct cellular localization and 
phenotype. The function of CPE-ΔN is in stark contrast to that of 
full-length WT CPE, the product of the primary transcript of the 
CPE gene, the role of which in the maturation of neuropeptides 
and peptide hormones in (neuro)endocrine cells is well estab-
lished. Our data provide compelling evidence that this variant 
of CPE, CPE-ΔN, increases cell proliferation, alters cell motility, 
and plays a role in inducing metastasis. Interestingly, we found 
that CPE-ΔN is expressed transiently in mouse embryos, suggest-
ing a possible physiological role in embryonic development (our 
unpublished observations).
Our siRNA suppression studies showed that CPE-ΔN promotes 
growth and invasion ex vivo in several types of human tumor cell 
lines and metastasis of human HCC cells in vivo in nude mice. 
Specifically, we demonstrated in low metastatic HCC cells trans-
fected with CPE-ΔN that the mechanism of induction of growth 
and invasion involves upregulating the expression of the Nedd9 
metastatic gene. The function and mechanism of action of the 
NEDD9 protein in tumor cell proliferation and metastasis are 
well documented (27).
Bioinformatic studies have identified a domain, homologous 
to HDAC-interacting proteins, in the CPE sequence (human 
CPE amino acids 111–196, with a consensus of 60%) (35). Analy-
sis of the molecular structure of CPE (41) revealed that part of 
this HDAC-binding domain comprises a loop structure that is 
exposed on the surface of the molecule, while some of it remains 
shallowly embedded but masked by the amino-terminal domain. 
Expression of a CPE protein without this amino-terminus, as in 
the case of CPE-ΔN, would result in an HDAC-binding domain 
that would be more accessible, thus allowing for an increase in 
the potential to interact with HDAC. Our studies showing co-
immunoprecipitation of CPE-ΔN with HDAC1 and HDAC2 in 
HCC cells demonstrate CPE-ΔN interaction with HDAC1/2. 
Perhaps CPE-ΔN may also interact with other members of the 
CHD3 complex, as suggested by a previous yeast two-hybrid high-
through-put protein-protein interaction study (34). Furthermore, 
using HDAC inhibitors, we showed that upregulation of Nedd9 
gene expression was dependent on a mechanism requiring histone 
deacetylase activity, which could lead to chromatin remodeling. 
Indeed, this corroborates clinical studies showing a direct correla-
tion between high levels of HDAC1 and tumor aggressiveness and 
shorter survival in patients with HCC (42).
Translating our findings to clinical studies, we demonstrated 
that quantification of the CPE-ΔN mRNA levels in primary tumors 
from HCC and PHEO/PGL patients by qRT-PCR can be used as 
a powerful tool for predicting future development of recurrence 
and metastatic disease (Tables 1–5 and REMARK in Supplemental 
Data). CPE-ΔN is the first highly reliable single-molecule prognos-
tic biomarker for HCC; other single markers such as α-fetoprotein 
are only useful for diagnosis and have no prognostic value (43, 44). 
Alteration in CPE-ΔN mRNA is easily detected, with a clear thresh-
old of 2-fold over expression in the primary tumor associated with 
Table 1
Correlation of CPE-ΔN mRNA expression with recurrence in 
HCC patients
Clinicopathological  CPE-ΔN expression 
variables
Recurrence at 2 years n T/N ≤2 T/N >2 Fisher P value
Yes 23 2 24 1.7 × 10–7
No 33 25 8 
OR, 37.5; 95% CI, 6.44–363.96.
Table 2
Sensitivity and specificity of CPE-ΔN as a biomarker for recur-
rence at 2 years
Parameter Value
CPE-ΔN mRNA (fold increase) 2
Sensitivity (%) 92.3
Specificity 75.8
Positive likelihood ratio 3.81
Negative likelihood ratio 0.10
Diagnostic OR 37.5
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prediction of future intrahepatic metastasis (recurrence) within 
2 years, with sensitivity and specificity values of 92% and 76%, 
respectively. Moreover, prediction of recurrence was highly corre-
lated with T/N ratio (>2) of CPE-ΔN mRNA, independent of can-
cer stage, demonstrating that it is superior to staging, currently 
used as a prognostic tool for HCC patients.
Measurement of the CPE-ΔN mRNA copy number in resected 
PHEO/PGL primary tumors established numbers in the millions for 
metastatic tumors versus hundreds of thousands for most benign 
tumors. More importantly, patients with tumors with CPE-ΔN 
mRNA copy numbers in the millions, but characterized as benign 
or non-metastatic at the time of surgery, were predicted to develop 
recurrent or metastatic disease, which subsequent follow-up studies 
indeed confirmed. Thus, CPE-ΔN is the only biomarker to date that 
could determine future metastasis and recurrence for PHEO/PGL 
patients diagnosed with benign tumors (Tables 4 and 5 and REMARK 
guidelines in Supplemental Data). With a poor out-
come defined as one when either the patient had 
metastatic disease at resection (SHDB) or developed 
recurrence after resection (MEN2), this biomarker 
achieved sensitivity and specificity values of 100% in 
this group of 14 patients (Tables 4 and 5).
In summary, the importance of this CPE-ΔN bio-
marker is that it is predictive of future development 
of recurrence as well as the metastatic potential 
and invasiveness of the tumor, based on CPE-ΔN 
mRNA present in the primary tumor, independent 
of tumor stage. Additionally, CPE-ΔN can also serve 
as a diagnostic biomarker to confirm metastasis 
diagnosed by other parameters. Furthermore, it is 
an advantage that this one biomarker can be used 
for predicting metastasis and recurrence in cancers 
with different origin, such as epithelial (HCC) and 
neuroendocrine cancers (PHEO/PGL). We showed 
that CPE-ΔN mRNA is also found to be elevated 
in metastatic breast, colon, and head and neck 
cancer cell lines (Figure 4). Additionally, others 
have found in high-throughput microarray studies 
that the elevation of CPE mRNA is correlated with 
tumorigenesis and metastasis in different types of 
human cancers, including cervical, colorectal, and 
renal cancers, Ewing sarcomas, and various types of 
astrocytomas and oligodendrogliomas (GEO Pro-
file ID: GDS 2416, GDS 2609, GDS505, GDS1813, 
GDS971; see Bioinformatics section in Methods). 
However, the form of the CPE transcript expressed in 
these tumors has not been investigated, and it may well be CPE-ΔN. 
Indeed, we recently carried out IHC studies and found immu-
nopositive staining for CPE in the nucleus of colon cancer cells that 
had metastasized to the liver in humans. This is consistent with the 
form of CPE in colon cancer being CPE-ΔN, especially since highly 
metastatic human colon rectal cancer cell lines express CPE-ΔN 
mRNA (Figure 4) but no WT CPE (our unpublished observations). 
Moreover, we also found that high levels of CPE-ΔN mRNA expres-
sion in the primary resected tumor is correlated with lymph node 
invasion and distant metastasis in patients with colon-rectal cancer 
(Supplemental Figure 7). Thus, CPE-ΔN could also potentially be a 
prognostic/diagnostic biomarker for those cancers shown in high-
throughput studies to express CPE mRNA. While CPE-ΔN appears 
to be a general cancer marker, its function as a prognostic marker 
for predicting future metastasis may be limited to specific cancers.
In conclusion, we have identified CPE-ΔN as an inducer of metas-
tasis, and it acts by translocation into the nucleus where it interacts 
with HDAC1/2 to upregulate NEDD9 metastatic gene expression, 
leading to enhanced proliferation, migration, and invasion of tumor 
cells. Its assay provides a major breakthrough in biomarker discov-
ery with invaluable utility in cancer prognosis for predicting future 
metastasis and recurrence in patients with HCC and PHEO/PGL, 
and potentially for other types of cancer as well. Moreover, CPE-ΔN 
could also be a useful target for therapeutic intervention (45).
Methods
Cell lines. Three lines of human oral squamous cell carcinoma (Tu167, 
Tu159, and MDA1986) (46), established from freshly resected human 
tumors, were obtained from Gary Clayman, University of Texas M.D. 
Anderson Cancer Center, Houston, Texas, USA. Human HCC cell lines 
Table 3
Comparative analysis of CPE-ΔN and cancer stage for recurrence 
at 2 years
 Non-recurrenceA RecurrenceA OR Fisher’s
Stage ≤2 >2 ≤2 >2  P value
1 (n = 2) 2/2 0/2 0/0 0/0 Not defined –
2 (n = 18) 10/13 3/13 1/5 4/5 13.3 0.047
3 (n = 24) 7/10 3/10 0/14 14/14 62.1 0.00035
4 (n = 12) 4/5 1/5 1/7 6/7 24.0 0.072
APatients with 2-fold or less, or greater than 2-fold CPE-ΔN/total number 
of patients.
Figure 7
Elevated CPE-ΔN mRNA expression in HCC tumors correlates with poor prognosis. 
(A) qRT-PCR quantification of hCPE-ΔN mRNA in tumor versus surrounding non-
tumor tissue in HCC clinical samples from n = 99 patients that were followed for 
recurrence (intrahepatic or extrahepatic metastases) for a median of 25.4 months 
after surgical resection (range, 0–110 months). Bar graphs show mean ± SEM 
(**P < 0.01) of T/N in the disease-free (blue) versus recurrence groups (red). (B) 
Kaplan-Meier plot of disease-free survival of n = 62 HCC patients (not used in deter-
mining expression level cut-point) stratified by CPE-ΔN expression levels. Patients 
with CPE-ΔN mRNA T/N levels greater than 2 (high) were compared with those with 
T/N of 2 or less (low). For CPE-ΔN (T/N ≤ 2), the median survival time was more than 
90 months. For CPE-ΔN (T/N >2), the median survival time was 8.6 months. Log-rank 
test showed significant differences between the 2 groups (P < 0.0001) (see Statistics 
for case-control sampling scheme).
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MHCC97L and MHCC97H, derived from the same parental cell line, and 
MHCCLM3 (47) were obtained from Liver Cancer Institute, Fudan Univer-
sity (Shanghai, China); H2P and H2M derived from the same parental cell 
line (12) were obtained from X.Y. Guan, Department of Clinical Oncology, 
University of Hong Kong, Hong Kong, China. Human colon cancer cell 
lines (HCT-116, HT-29, and SW480) and human breast cancer cell lines 
(MDA-MB-231, T47D, and MCF-7) were obtained from ATCC.
Bioinformatics. A non-redundant nucleotide sequence database search was 
carried out with human and mouse CPE nucleotide sequence as queries 
(NM_001873.2 and NM_013494.3, respectively). Potential spliced variants 
(Genbank AK090962 and BY270449) were screened based on differences in 
nucleotide sequence between the query and the subject sequences. Specific 
primers at the splice junctions were designed to amplify these variants by 
PCR in MHCC97 cells. CPE microarray data were mined from GEO Profile 
data (http://www.ncbi.nlm.nih.gov/geo/).
Semiquantitative PCR of WT CPE and CPE-ΔN transcripts in HCC cells. RNA 
was extracted from MHCC97L and MHCC97H using the RNeasy Mini 
Kit (QIAGEN), and first-strand cDNA was synthesized with 1 μg of total 
RNA from these cells using Transcriptor First Strand cDNA Synthesis Kit 
(Roche Applied Science). Semiquantitative PCR was performed to quan-
tify CPE-ΔN transcripts using GoTaq Green Master Mix (Promega). 18S 
RNA was used for normalization. Primer sequences specific for the human 
ΔN-splice variant CPE-ΔN RNA were fwd: 5′-ATGGCCGGGCATGAG-
GCGGC-3′, rev: 5′-GCTGCGCCCCACCGTGTAAA-3′. Primer sequences 
for amplifying 18S RNA were fwd: 5′-CTCTTAGCTGAGTGTCCCGC-3′, 
rev: 5′-CTGATCGTCTTCGAACCTCC-3′. cDNA (0.2 μg) from MHCC97L 
and MHCC97H cells was used for every reaction. PCR cycling was at 94°C 
for 15 seconds, annealing at 65°C for 30 seconds, extension at 72°C for 
30 seconds, and a final extension at 72°C for 10 minutes. Eighteen microli-
ters of each sample was removed every 3 cycles from 24 to 35 cycles in each 
reaction to amplify CPE-ΔN and 18S fragments. Amplified PCR products 
were separated on 1.5% agarose gels with Tris-borate EDTA buffer and 
stained with ethidium bromide. Gels were captured as digital images and 
the bands quantified by densitometry (ImageJ).
qRT-PCR of CPE-ΔN in cell lines and clinical HCC specimens. RNA was extracted 
from cancer cells (described above) and patient’s tumor and surrounding 
non-tumor tissue using TRIzol reagent (Invitrogen). Complementary DNA 
amplified from mRNA in the tissues was subjected to qRT-PCR for CPE-ΔN 
expression using Fast SYBR Green Master Mix PCR kit (Applied Biosystems); 
cycling conditions were 95°C for 5 minutes, followed by 40 cycles of 95°C 
for 15 seconds, 62°C for 60 seconds. Reactions were performed using an ABI 
PRISM 7900 Sequence Detector (Applied Biosystems). Fluorescence signals 
were analyzed using SDS 1.9.1 software (Applied Biosystems). 18S rRNA was 
used as an endogenous normalization control. Primer sequences for CPE-ΔN 
RNA and 18S rRNA were as outlined above. All qRT-PCRs were performed in 
duplicate and averaged to obtain the data point for each specimen. The rela-
tive amount of CPE-ΔN mRNA was normalized to an internal control, 18S 
Figure 8
Elevated expression and nuclear localization of CPE-ΔN protein in metastatic HCC tumor tissue. (A) Western blots showing hCPE-ΔN in primary 
HCC tumors and surrounding tissue from 4 disease-free patients (upper panel) and 4 patients with recurrence (lower panel). (B) The CPE-ΔN 
band intensity in such blots for n = 80 HCC patients (different from above) were quantified and normalized to the level of actin in the samples. 
Bar graphs show mean ± SEM (***P < 0.001) of T/N for proteins in disease-free (white) and recurrence (black) groups at 6-month follow-up. 
(C and E) IHC on primary HCC tumor and adjacent normal hepatic parenchyma (D and F) from patients with (C and D) and without recurrence 
(E and F). CPE-ΔN staining is predominant in nuclei of cancer cells in the patient with recurrence (C) (arrows). Scale bars: 20 μm (C–F).
Table 4
CPE-ΔN mRNA copy number in SDHB/D and MEN2 PHEO/PGL 
tumors and prediction of metastasis and recurrence
Sample  DiagnosisA Genotype Copy no. Follow-up  
no.    statusB
S55 BenignC SDHD 167,550 Disease freeD (4 yr)
S85 BenignC SDHD 187,809 Disease free (2 yr)
S73 BenignE SDHB 200,000 Disease free (2.5 yr)
S82 BenignE SDHB 200,714 Disease free (2.4 yr)
S31 BenignE SDHB 11,894,562 Metastatic (2 yr)
S18 Metastatic SDHB 5,583,686 Metastatic
S22 Metastatic SDHB 10,937,462 Metastatic
S95-A-1 Metastatic SDHB 6,181,873 Metastatic
M20 Metastatic SDHB 11,057,100 Metastatic
M12 BenignC MEN2 194,801 Disease free (6.5 yr)
M13 BenignC MEN2 190,139 Disease free (6 yr)
M15 BenignC MEN2 168,984 No follow-up  
    information
M06 RecurrentF MEN2 6,750,151 Recurrent (4 yr)
M05 BenignC MEN2 14,825,680 Recurrent (8 yr)
ADiagnosis at time of surgery. BYears of follow-up or time to recur-
rence/metastasis. CBenign adrenal. DNo clinical symptoms or signs of 
disease, with negative imaging and biochemical data where applicable. 
EBenign extra-adrenal. FRecurrent in contralateral adrenal surgical 
bed. Benign: no metastatic lesions; recurrent: reappearance in surgical 
bed; metastatic: presence of tumor at sites where chromaffin cells not 
normally present. Patients S22 and M20 died of metastatic disease at 4 
and 3 years, respectively, after surgery; S18 and S95 show progressive 
metastatic disease since surgery.
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RNA, and to a calibrator, given by Livak and Schmittgen (48): 2−ΔΔCT, where 
ΔΔCT = (CT[CPE] − CT[18S])test − (CT[CPE] − CT[18S])calibrator. The thresh-
old value (CT) was defined as the fractional cycle number at which the amount 
of amplified target reached a fixed threshold. The CT value correlates with the 
input target mRNA levels, and a lower CT value indicated a higher starting 
copy number. One of the samples was designated as the calibrator to compare 
the relative amount of target in different samples and used to adjust for plate-
to-plate variation in amplification efficiency. The relative expression level of 
CPE of each patient was evaluated as the relative fold change in log2 scale.
Determination of CPE-ΔN mRNA copy numbers in PHEO/PGL. Total RNA 
was extracted from frozen PHEO/PGL tumor pieces after homogenization 
in TRIzol reagent (Invitrogen) followed by RNeasy Mini kit (QIAGEN) 
according to the manufacturer’s recommendations. Total RNA (0.2 μg) 
was then converted to cDNA using the Roche First Strand cDNA Synthe-
sis Kit. CPE-ΔN mRNA copy numbers were determined by setting up a 
standard curve using known concentrations of hCPE cDNA. A complete 
clone of hCPE cDNA was excised from its plasmid and purified, and its 
concentration determined spectrophotometrically. The conversion of 
microgram value to picomoles was performed using the following for-
mula: pmol of dsDNA = μg (of dsDNA) × 106 pg/1 μg × 1 pmol/660 pg 
× 1/Nbp (where Nbp is length of the amplicon in bp). Serial dilutions of 
the cDNA were made and used as templates for qRT-PCR to generate a 
standard curve. The qRT-PCR was carried out in triplicate for 8 different 
concentrations using primers specific for hCPE (fwd: 5′-CCATCTCCGT-
GGAAGGAATA-3′ and rev: 5′-CCTGGAGCTGAGGCTGTAAG-3′). The 
crossing point was determined from the qRT-PCR program and averaged 
for each point and plotted as a function of the starting template concen-
tration, expressed as template copy number. For the PHEO/PGL samples, 
conditions in the qRT-PCR using CPE-ΔN specific primers were: initial 
denaturation for 5 minutes at 95°C, followed by 45 cycles of 15 seconds 
at 95°C, 15 seconds at 62°C, and 5 seconds at 72°C. The PCR reaction 
was followed by a melting curve program (65–95°C) with a heating rate 
of 0.1°C per second and a continuous fluorescence measurement and a 
cooling program at 40°C. Crossing-point values were converted to copy 
numbers using the standard curve described as above. Negative controls 
consisting of no-template (water) reaction mixtures were run with all reac-
tions. PCR products were also run on agarose gels to confirm the forma-
tion of a single product of the predicted size.
Verification of lack of WT CPE in HCC cells and human HCC. Since we were 
not able to design primers that specifically amplified the human WT 
CPE mRNA only, we used an alternative method to determine whether 
MHCC97H cells and human HCC contain WT CPE. This method involved 
initially setting up a standard curve as described above. The mRNA copy 
numbers in the MHCC97H cells and HCC were compared using the set of 
generic primers (as described above) that amplifies both WT and CPE-ΔN 
cDNA and using the primers specific for hCPE-ΔN only. Conditions for the 
qRT-PCR for CPE using both sets of primers were: initial denaturation for 3 
minutes at 95°C, followed by 45 cycles of 15 seconds at 95°C, 15 seconds at 
62°C, and 5 seconds at 72°C. The PCR reaction was followed by a melting 
curve program (65–95°C) with a heating rate of 0.1°C per second and a con-
tinuous fluorescence measurement and a cooling program at 40°C. Nega-
tive controls consisting of no-template (water) reaction mixtures were run 
with all reactions. PCR products were run on agarose gels to confirm the 
formation of a single product of the predicted size. We found that the copy 
numbers in the HCC cells using either the generic primers or the CPE-ΔN– 
specific primers to be the same, indicating that MHCC97H cells and HCC 
tumors lacked WT CPE. Additionally, Western blots of MHCC97H cells 
and human HCC samples, using human WT CPE expressed in COS7 cells 
as a positive control, showed no WT CPE band.
Western blot for CPE-ΔN and NEDD9 in cell lines and clinical HCC specimens. 
Proteins from clinical specimens were prepared using urea buffer (8 M 
urea, 10 mM Tris pH 7). Briefly, frozen tissue blocks were homogenized, 
and cells were placed on ice for 15 minutes and then centrifuged at 13,000 g 
for 5 minutes at 4°C. The supernatant was collected and its protein concen-
tration determined. Proteins from human cancer cell lines were prepared 
using cell lysis buffer (Cell Signaling Technology) supplemented with Com-
plete Inhibitor Cocktail (Roche) to prevent protein degradation. The cell 
lysate was collected and centrifuged at 15,000 g for 10 minutes at 4°C and 
the protein concentration in the supernatant determined. Twenty micro-
grams of protein was denatured, run on 4%–20% or 12% SDS-PAGE gels, and 
transferred onto nitrocellulose membrane or PVDF membrane (Millipore), 
according to standard protocols. After blocking with 5% nonfat milk at 
room temperature for 1 hour, CPE-ΔN on the membrane was detected using 
a mouse anti-CPE monoclonal antibody directed against the 49–200 amino 
acid sequence (BD Biosciences) at 1:4,000 dilution. NEDD9 was detected 
with mouse anti–human HEF1 generated using the N-terminal 82–398 
amino acid sequence of NEDD9 (clone 14A11 at 1:1,000 dilution; Rockland 
Immunochemicals) and rabbit polyclonal N-terminal antibody, a gift from 
Chikao Morimoto (Tokyo University, Tokyo, Japan). Following primary 
antibody binding, the membrane was incubated with horseradish peroxi-
dase–conjugated anti-mouse or anti-rabbit antibody (Amersham) and then 
visualized by enhanced chemiluminescence plus according to the manufac-
turer’s protocol. The intensity of the bands was quantified by densitometry 
and expressed as arbitrary units (AU). The expression of CPE-ΔN 
and NEDD9 levels of each cell line was corrected for their actin level and 
expressed as the mean ± SEM of AU from 3 separate experiments.
Lentivirus-based suppression of CPE-ΔN and NEDD9 in tumor cell lines. Lenti-
viral particles (Dana Farber Cancer Institute–Broad Institute RNAi Con-
sortium) expressing shRNAs against human CPE and human NEDD9 
were used to downregulate their mRNA. Transduced cells were selected 
with 2 μg/ml puromycin. For CPE, initially 3 shRNAs were used: CPE-
sh1-CCGGCCAGTACCTATGCAACGAATACTCGAGTATTCGTTG-
CATAGGTACTGGTTTTTG; CPE-sh2-CCGGCTCCAGGCTATCTG-
GCAATAACTCGAGTTATTGCCAGATAGCCTGGAGTTTTTG; and 
CPE-sh3-CCGGGATAGGATAGTGTACGTGAATCTCGAGATTCACG-
TACACTATCCTATCTTTTTG. Subsequently, lentivirus CPE-sh2 was used 
in the tumor cell lines described in Figure 2. For Nedd9, the shRNA used 
was Nedd9-sh1-CCGGCGTGGAGAATGACATCTCGAACTCGAGTTC-
GAGATGTCATTCTCCACGTTTTT. A scrambled shRNA lentivirus was 
used as the negative control.
Immunofluorescence of CPE-ΔN in HCC tumor cells. MHCCLM3 cells trans-
fected with either si-scrambled or si-CPE, which downregulates CPE-ΔN 
mRNA expression, were cultured on chambered slides, permeabilized with 
0.1% Triton X-100, and fixed with 4% paraformaldehyde in PBS. The cells 
were incubated with monoclonal antibodies against carboxypeptidase E 
(1:100) (BD Biosciences). The secondary antibody was TRITC-conjugated 
goat anti-mouse IgG (Molecular Probes, Invitrogen). The slide was subse-
Table 5
Sensitivity and specificity of CPE-ΔN as a biomarker for PHEO/
PGL: metastatic disease at resection or recurrence after resection
CC cut-point (×105) SN SP PLR NLR DOR 
2.5 100 100 NA NA NA
5 100 100 NA NA NA
10 100 100 NA NA NA
CC, CPE-ΔN mRNA copy number; SN, sensitivity; SP, specificity; 
PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, 
diagnostic OR.
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quently stained with fluorescein phalloidin (Molecular Probes, Invitrogen) 
in 1% BSA (dilution factor, 1:50) at 37°C for 1 hour and counterstained 
with DAPI (AppliChem GmbH). All images were visualized by confocal 
microscopy, and photographs were taken at ×600 magnification. While 
the antibody used detects both CPE-ΔN and WT CPE, the latter is not 
expressed in HCC cells; thus, the immunostaining reflects CPE-ΔN.
Immunoprecipitation of CPE-ΔN and HDAC. For immunoprecipitation 
experiments, MHCC97L cells (2 × 107) were plated on 150-mm-diameter 
dishes and transduced with CPE-ΔN adenovirus. Cells were lysed in 1 ml 
whole-cell lysis buffer (Active Motif) with a cocktail of protease inhibitors, 
phosphatase inhibitors, and 0.5 mM PMSF (Active Motif) on ice. Insoluble 
cell debris was removed by centrifugation at 13,000 g for 15 minutes at 4°C. 
500 μg of the soluble extract was subjected to immunoprecipitation by 
incubation with CPE, HDAC1 (Millipore Temecula), or nonspecific mono-
clonal antibodies for 1 hour at 4°C on a rolling shaker. The mixture was 
then incubated with 25 μl protein G magnetic beads (Invitrogen) overnight 
at 4°C. The beads with bound immune complexes were captured by plac-
ing the tubes on a magnetic stand. The supernatant was removed, and the 
beads were washed 5 times with ice-cold Co-IP wash buffer (Active Motif), 
resuspended in 1× sample buffer, and analyzed by Western blot with CPE, 
HDAC1 monoclonal, or HDAC2 (Abcam, 16032) polyclonal antibody.
Treatment of HCC cells with HDAC inhibitors. HDAC inhibitors TSA (obtained 
from Sigma-Aldrich) and romidepsin (depsipeptide, a gift from Alan Colo-
wick, Gloucester Pharmaceuticals, Cambridge, Massachusetts, USA), both 
dissolved in DMSO, were diluted with media immediately before use. In 
control experiments without inhibitors, DMSO was added to control cells. 
Human MHCC97L cells expressing CPE-ΔN were plated at equal densities at 
37°C, 5% CO2 in DMEM medium supplemented with 10% fetal calf serum, 
sodium pyruvate (0.11 mg/ml), penicillin (100 U/ml), and streptomycin 
(100 mg/ml). After 24 hours, cells were treated with different concentrations 
of TSA or depsipeptide for 24 hours and then harvested. The nuclear and 
cytosolic fractions were extracted by a nuclear extraction kit (Active Motif) 
according to the manufacturer’s instructions. The cytosolic and nuclear frac-
tions were analyzed by Western blot for NEDD9 protein levels.
Patient samples of HCC. For a retrospective blinded study, written informed 
consent was obtained from patients, and HCC samples were collected 
under University of Hong Kong (UHK) IRB–approved protocol UW 05-359 
T/1022. All patients underwent hepatectomy for HCC in the Department 
of Surgery, UHK. HCC samples used for Western blotting were obtained 
from 80 patients who underwent hepatectomy for HCC from 2002 to 
2005; 46 of them developed intrahepatic (recurrence) or extrahepatic 
metastasis within 6 months of surgery, while the other 34 remained dis-
ease free during that time. For primary HCC analyses, based on RT-PCR 
of mRNA and IHC, 100 patients were chosen retrospectively from a pool 
of eligible HCC patients. The patients underwent surgical resection for 
HCC between 2000 and 2005 and were eligible so long as they had perti-
nent clinical data and specimens available for assay, had not been treated 
prior to tumor resection, and had no further treatment beyond the tumor 
resection. These patients had all stages of disease, with roughly 75% hav-
ing stages 2 or 3; their follow-up was very variable, ranging from less than 
1 month to more than 9 years. The sampling design was an unmatched 
case-control selection with no matching for factors such as age or sex; how-
ever, the sampling resulted in the subsets of recurrers and non-recurrers 
being very similar with respect to mean age (54.0 vs. 53.7 years, respectively) 
and breakdown by sex (78.1% males vs. 84.3% males, respectively). Since 
one patient did not have usable normal tissue available, all analyses used 
a set of 99 patients. Due to limited follow-up in a few patients, only 92 of 
the 99 were analyzable for the primary end point of 2-year recurrence. The 
end of the follow-up period was September 2009, with a median follow-up 
of 25.4 months. To establish a cut-point for prediction of extrahepatic or 
intrahepatic metastasis (recurrence), CPE-ΔN mRNA from resected pri-
mary tumor and surrounding normal tissue from a subset of 37 of the 
99 HCC patients (the “pilot” or “training” set) was used. A cut-point T/N 
value of 2 was established — ratios above this cut-point indicated likely 
tumor recurrence within 2 years. This cut-point provided a near optimal 
balance between sensitivity and specificity in this subset of patients. The 
remaining 62 of the 99 patients were used to predict, using the cutoff of 2 
for the T/N ratio, which patients would be disease-free and which would 
experience recurrence within 2 years. Similarly, the 80 patients with protein 
levels established by Western blot, were evaluated for recurrence within 
6 months after surgery, comparing protein T/N ratios between those with 
recurrence and those without. Although not prospectively evaluated at this 
cut-point, a protein T/N ratio greater than 2 again appeared to be highly 
correlated with recurrence during this time period.
HCC patient follow-up and survival analysis. All patients were followed 
monthly in the first year and thereafter quarterly, with regular monitoring 
for recurrence by serum α-fetoprotein level and ultrasonography or CT 
scan of the liver. The diagnosis of recurrence was based on typical imag-
ing findings on CT or arteriography and, if necessary, percutaneous fine-
needle aspiration cytology. Recurrence of the disease was analyzed without 
further delineation into intrahepatic or extrahepatic. Disease-free survival 
was measured from the date of hepatic resection to the date when recur-
rent disease was diagnosed or, in the absence of detectable tumor, to the 
date of death or the last follow-up. Actuarial survival was measured from 
the date of hepatic resection to the date of death or the last follow-up.
Tumor samples and clinical pathology of PHEO/PGL patients. For a prospec-
tive blinded study, all PHEO and PGL patients were enrolled and patient 
samples collected under IRB-approved protocol 00-CH-0093 at the NIH, 
Bethesda, Maryland, USA. Results for all n = 14 patients are included in this 
report (no selection of cases). All patients provided written informed con-
sent, and all but one were followed for a minimum of 2 years after resection 
of their primary tumors. Upon resection, the tissue specimen was placed 
in a sterile container on ice and transported for immediate examination by 
a pathologist, and tissue that was not necessary for diagnostic purposes 
was dissected from the tumor, excluding necrotic areas and tumor margin 
or capsule. Further dissection into pieces no larger than 0.5 × 0.5 × 0.5 cm 
was performed on ice, and samples were frozen directly in liquid nitrogen.
Immunostaining and quantification of CPE-ΔN in human tissue sections. HCC 
tumor tissue and surrounding non-tumor tissue were formalin fixed and 
paraffin embedded. Four-micrometer sections were cut, dewaxed in xylene 
and graded alcohols, hydrated, and washed in PBS. After pretreatment 
in a microwave oven (12 minutes in sodium citrate buffer [pH 6]), the 
endogenous peroxidase was inhibited by 0.3% H2O2 for 30 minutes, and 
the sections were incubated with 10% normal goat serum for 30 minutes. 
Mouse monoclonal anti–carboxypeptidase E (1:100) (R&D Systems) was 
applied overnight in a humidity chamber at 4°C. (While the antibody 
used detects both CPE-ΔN and WT CPE, the latter is not expressed in 
HCC; thus, the immunostaining reflects CPE-ΔN.) A standard avidin-bio-
tin peroxidase technique (Dako) was applied. Briefly, biotinylated goat 
anti-mouse immunoglobulin and avidin-biotin peroxidase complex were 
applied for 30 minutes each, with 15-minute washes in PBS. The reaction 
was finally developed with the Dako Liquid DAB+ Substrate Chromogen 
System (Dako). Slides were imaged on an Aperio Scanscope CS imager, 
generating 0.43-μm/pixel whole slide images. These images were compiled 
and analyzed using the Aperio Spectrum software with a pixel count algo-
rithm (49). Quantified expression of tumor tissue minus adjacent normal 
tissue was compared for patients with and without recurrence.
Statistics. The primary statistics used for non-patient samples were means 
and SEMs for descriptive statistics, and standard unpaired t tests for com-
paring independent observations (paired versions for comparing paired 
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observations). The statistical methods used for the PHEO/PGL section are 
descriptive, with no formal analyses being presented due to the small num-
ber of patients and their variable follow-up. Table 4 shows all pertinent 
data for the 14 patients. Although Table 5 shows several sensitivity/speci-
ficity values, they are only illustrative, emphasizing what is apparent from 
the patient-by-patient data listing: copy numbers divide into two very sepa-
rate groupings; and, using current patient follow-ups, these copy numbers 
perfectly separate those having a bad outcome — defined as either being 
metastatic at resection or developing recurrent or metastatic disease dur-
ing follow-up — from those having a good outcome.
For HCC patients, standard t tests (and means and SEMs) are reported 
for comparing — either in the group of 99 patients evaluated for mRNA by 
qRT-PCR or the group of 80 patients evaluated by Western blot for protein 
— the levels of these products in those with recurrence and those without. 
The primary end point for HCC patients was 2-year recurrence in the 99 
patients with mRNA T/N ratios. A training subset of 37 patients from this 
group was used to evaluate potential T/N cut-points; using these results, a 
cut-point of 2 was established, based on its excellent sensitivity and speci-
ficity. This cut-point was then evaluated on the remaining 62 patients — 
the test subset. The training and test sets were very similar with respect to 
recurrence rates and other patient characteristics: in the training set, 45.5% 
experienced recurrence by 2 years versus 44.1% in the test set; the mean ages 
were 53.5 years and 55.1 years, respectively; and the proportions of males 
were 78.4% and 85.5%, respectively.
Using 2-year (very similar results were obtained using 3 years) recur-
rence as the primary end point was dictated by the initial case-control 
selection of 50 recurrers and 50 non-recurrers from the full population; 
because this was not a random selection from the population, there 
is the potential that survival-based analyses could lead both to biased 
estimates of survival curves and to statistical tests giving erroneous 
P values (see ref. 50 for a study, based on actual data, of the possible asso-
ciated problems). Using a dichotomous outcome eliminates this prob-
lem. Basing analyses on ORs or Fisher’s exact test insures the validity of 
the results (see ref. 51 regarding the applicability of OR-based methods, 
including logistic regression and Fisher’s test, for case-control designs). 
With 2-year recurrence as the end point, 92 of the 99 had sufficient fol-
low-up for analysis: 33 of 37 in the training set and 59 of 62 in the test 
set. Since 2-year follow-up captured 41 of all 50 recurrences (82%), only a 
small amount of information was lost (analyses using 3-year recurrence 
captured 47 of the 50 recurrences). Any small loss of power was irrel-
evant, since the primary P values were around 10–7. Besides standard esti-
mates of ORs, their exact CIs, and exact P values based on Fisher’s test 
(StatXact, Cytel Software Corp.), logistic regression was used to assess 
whether CPE-ΔN added significantly to a model with cancer stage (the 
only standard prognostic variable for this disease) as a predictor (Stata). 
This was the only multivariate analysis, and the only one involving any 
modeling assumptions.
To complement these analyses of 2- and 3-year recurrence rates, we 
present a Kaplan-Meier plot and log-rank P value for time to recurrence, 
although case-control sampling may introduce some bias (and we did not 
have the data that could “adjust” the nominal log-rank P value to account 
for the bias). Our 3-year recurrence rate was 52.5%, very similar to the 
48.2% seen in the full population of n = 317; hence, the bias in the Kaplan-
Meier estimates should be only a few percent (similar to ref. 50), which is 
swamped by the enormous differences between the two survival curves in 
Figure 7B. The nominal log-rank P value (<10–9) is likely too small, due to 
case-control sampling bias and the c2 approximation; however, the valid 
OR P values at 2 or 3 years were 1.7 × 10–7 and 2.2 × 10–6, so a valid log-rank 
P value should be in a similar range; to be conservative, we simply report 
it as less than 0.0001.
Other methods. Colony formation assay, Matrigel invasion assay, animal 
studies, and Northern blotting are presented in Supplemental Data.
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